Constipation is considered an inconvenient problem, however data on the real burden is lacking. The objective of the current analysis was to assess the clinical and economic burden of chronic constipation in Belgium. METHODS: From the IMS Hospital Disease Database (year 2007), which includes data on full hospitalizations and day clinic for 34.3% of Belgian hospital beds, stays of patients with constipation were selected based on the ICD-9-CM code (564.0) with constipation as a primary diagnosis. The database allows to estimate length of stay (LOS), inhospital mortality, performed interventions, ATC classified medication usage, and cost of hospitalisation. Using the 34% coverage, a national projection was made for the number of hospital stays and burden of disease. 2007 costs were extrapolated to 2010 using progression in costs from 2001 to 2007. ATC codes for osmotic/contact laxatives, softeners, bulking agents, enemas and peripheral opioid receptor antagonists were used. Occurrence of relevant co-morbidities was analyzed using applicable ICD-9-CM codes. RESULTS: There were 6338 hospital day clinic stays and full hospitalizations (LOS 5.44 days). About 42% of the patients were admitted via the ER. Most occurring co-morbidities were hemorrhoids (174), fecal impaction (74) and intestinal obstruction (53). Mortality rate was 0.46% meaning 29 deaths in hospitalizations for constipation. Especially in hospitalized patients, usage of enemas was pronounced (34.17%). Osmotically acting laxatives are the most used agents (39.58%). The average costs per patient was €1883, consisting of medication costs, procedural costs and stay costs of €112, €675 and €1097, respectively. Extrapolated to Belgium the total hospitalization cost for constipation was approximately €11.9 million. Hospital stay is more frequent in the elderly particularly in elderly females. CONCLUSIONS: Constipation is an underestimated disease condition reflected by hospital related costs of about €11.9 million and approximately 29 death cases in Belgium in 2007. 
OBJECTIVES:
The aim of this study was to assess disease stage dependent resource use and costs in chronic genotype 1 hepatitis C (CHC) patients in Belgium.
METHODS:
The medical records of 157 CHC patients were reviewed to identify medical costs over a follow up period of 3 years. Six disease stages were defined based on histology/clinical data: mild disease (F0-F2), moderate disease (F3) or compensated cirrhosis without varices (F4), compensated cirrhosis with varices (F4), decompensated cirrhosis, hepatocellular carcinoma (HCC) and liver transplantation (LT). Data collected were baseline demographic characteristics, HCVrelated data and detailed resource use (hospitalizations, day-clinic visits, surgery/ interventions, physician visits, diagnostic tests and drug use). Resource use items were multiplied with unit costs (2010) to calculate costs. The public health care payer's (HCP) perspective was taken including the health insurance and patient co-payment. RESULTS: Intravenous/intranasal drug use was reported in circa 20% of patients, 63% had co-morbidities at study start. Nineteen patients (12%) died during the study period, whereof 79% attributable to HCV. Average number of hospitalizations during the study period ranged between 0.4 (mild disease) and 5.3 (HCC). Cost of care during the study period ranged from €18,993 for mild disease (in 81% due to HCV drug treatment) to €35,987 for patients with HCC (in 83% due to hospitalization, 11% due to medication and in 6% due to ambulatory care) and €65,120 for patients who underwent a liver transplant (79% hospitalization, 18% medication, 3% ambulatory care). Cost of diagnosis of the disease stage ranged between €790 (F3-F4 without varices) and €4142 (decompensated cirrhosis). CONCLUSIONS: Antiviral treatment is the most important cost driver in mild & moderate disease, but once complications of CHC occur, the associated costs far exceed this cost of antiviral therapy. OBJECTIVES: Hepatitis C (HCV) is a disease which in the long run can lead to cirrhosis and liver cancer, resulting in liver transplantation or death if not treated properly. So far, there is a paucity of literature on health care costs and quality of life (QoL) of HCV management. This study aims to illustrate the health care costs and QoL associated with HCV in The Netherlands. METHODS: This study followed a cross-sectional design for QoL and indirect costs, and a retrospective design for direct costs (these were mapped retrospectively until 3 years ago or diagnosis of HCV if earlier). Patients with HCV genotype 1 at Erasmus MC were invited to participate between November 2010 and April 2011. Patients were asked to complete the EQ-5D, Short form 36 (SF-36), Liver disease symptom index (LDSI) and Short form health and labour questionnaire (SF-HLQ). Resource use data were collected from the hospital information system. Utilities were determined using the UK tariff for EQ-5D The Mann-Whitney U-test was used for comparisons between treated and non-treated patients for the disease categories, mild and moderate disease and cirrhosis. RESULTS: Thirty-seven patients had either completed or discontinued treatment during the observation period, 10 had achieved sustained viral response (SVR). Mean direct costs were higher for treated patients, during all 3 years of observation; 3286 versus 5361, 1336 versus 9440, 2538 versus 10.507, (pϽ0.01). Compared to non-responders successfully treated patients had lower follow-up costs 1 year after treatment, 1172 versus 1426, and a higher mean utility, 0.84 versus 0.70, neither result was statistically significant at pϭ0.4 and pϭ0.2. There were no significant differences in indirect costs. CONCLUSIONS: This study provides basic information about the costs and utility of hepatitis C treatment. Such information is valuable when considering cost-effectiveness of new treatments for this disease. Fusco F Charta Foundation, Milano, Italy OBJECTIVES: As a result of successful treatments for chronic hepatic diseases (CHDs), patients' life expectancy, but also the diseases prevalence and costs are increasing. However, societal costs for CHDs remain little known. We assessed treatment and productivity costs of patients with CHDs in Italy. METHODS: a naturalistic multicentre Cost-of-Illness study was conducted. Adult patients (ageϾ18 years) diagnosed with CHDs, consequently accessing at gastroenterology unit of 2 hospitals, were enrolled. Direct and indirect costs were assessed from the societal perspective, reported as mean €/patient-month (treatment cost) and mean days/ patient-month of work/school/usual activities lost (productivity loss). The patients were sub-grouped according to their main condition at the enrollment: hepatitis B, hepatitis C, cirrhosis, liver transplantation, hepatic carcinoma. RESULTS: We enrolled 1,088 valid patients, 62.0% male (Nϭ675), aged 19-90 (medianϭ60) years: 31.5% (Nϭ342) has hepatitis C, 20.3% (Nϭ220) cirrhosis, 19.8% (Nϭ216) hepatitis B, 11.9% (Nϭ129) had liver transplantation, 7.5%(Nϭ82) hepatic carcinoma, 9.0% (Nϭ99) had other hepatic diseases. Overall, their treatment cost was 278.26 €/patient-month: 96% for conventional drug treatment, 4% for unconventional treatment (homeopathy, preparation of herbs, specific diet, multi-vitamin products). Patients who received liver transplantation were the most expensive (1041.31€/ patient-month), followed by hepatitis B (249 €/month), hepatitis C (167 €/month). Productivity loss corresponded to 4.9 days/patient-month, mainly by transplanted patients (8.6 days/patient-month) and those with cirrhosis (8 days/patient-month). CONCLUSIONS: CHDs sensitively contribute to the high cost and require appropriate health technology valuations to guide stakeholders to find optimal diagnostic and treatment strategies. 
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PGI17 COST OF OUTPATIENT ENDOSCOPIC CAPSULE (EC) PROCEDURE IN BRAZIL: A STUDY FROM A PAYER'S PERSPECTIVE
OBJECTIVES:
There is no published study about the direct costs linked to the procedure of the EC in Brazil. Our aim was to determine a base price of a single procedure of EC. METHODS: Based on a micro cost approach, we first determined the individual items that compose an EC procedure. Then we conducted a market price search for each of them in order to compose the final total cost. For the permanent equipment needed we considered an amortization time of 24 months and a 1% monthly interest percent rate. RESULTS: An EC procedure requires an initial investment in one computer and in one receiver, which is attached to the patient to capture the capsule's signal, known as "belt". Included in the analysis there are also the cost of the capsule per si, some medicines, the physician's and the room fee. The initial investment is US$19,411. Each capsule cost US$647 (single use). A medical fee of US$380 was set, that include the administration of the capsule, the supervision of the patient during the length of the procedure and the interpretation of the exam. Considering a service that performs three exams a month, a cost of US$1645 would be necessary to cover the expenses with material, personnel (doctors included) and to pay the amortization costs, insurance and interests for a 24 months period. CONCLUSIONS: In Brazil, the cost of EC procedure may be set at US$1645 in order to cover the expenses of the services.
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